A one year, randomised, double blind, placebo controlled trial of probiotics. Bifidobacterium infantis 35624 or Lactobacillus salivarious UCC118, as food supplements for maintenance of remission in Ulcerative colitis.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN11348435

Enrollment

180

Registered

2004-09-30

Start date

2001-10-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System: Ulcerative colitis Digestive System Ulcerative colitis

Interventions

1. Bifidobacterium infantis 35624 2. Lactobacillus salivarious UCC118 3. Placebo July 2008: no patients enrolled in this trial.

Eligibility

Inclusion criteria

Inclusion criteria: 120 patients, 60 control patients.

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
A failure to maintain remission over a period of 1 year. Using the simple ulcerative colitis activity index, a score of >- 7 indicates relapse. (i.e. Relapse - CAIA >- 7 and/or a requirement for clinical intervention e.g. drugs/surgery etc.)	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026